Connect with us


Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch

Biotech penny stocks to watch this week.
The post Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch appeared first on Penny Stocks…



If you’re an active trader or looking for stock market news today, this is probably the one-millionth headline you’ve read with the phrase “Recession Begins” in the title. Apologies for that, but it’s true; we’re officially in a technical recession. For those unfamiliar with the definition of a recession, it’s two consecutive quarters of negative GDP growth.

Today’s second quarter GDP data showed that Q2’s gross domestic product fell 0.9%. This came after the first quarter’s contraction of 1.6% and a staunch difference from how the year ended in 2021. With the definition of recession being met, some may find it interesting that markets aren’t completely failing. That’s likely because of a tighter labor market and that consumers are still spending. Nevertheless, the point is that (for now) recession isn’t scaring the stock market today.

Better yet, there is still somewhat of a risk-on appetite for things like penny stocks. Today we look at the biotech sector for some of the hot stocks to watch today. While the overall biotech market is trending lower, small- and micro-cap stocks are giving some reprieve at the moment.

Biotech Penny Stocks To Watch

  1. Comera Life Sciences Holdings (NASDAQ: CMRA)
  2. Athersys, Inc. (NASDAQ: ATHX)
  3. InflaRx N.V. (NASDAQ: IFRX)
  4. Revelation Biosciences Inc. (NASDAQ: REVB)
  5. Chimerix (NASDAQ: CMRX)

Comera Life Sciences Holdings (NASDAQ: CMRA)

Comera Life Sciences is one of the penny stocks to watch as shares have steadily risen this week. The company specializes in transitioning IV medicines to subcutaneous forms and provides patients with self-injectable care.

Earlier this month, Comera announced preclinical topline safety results of its SQore excipient platform.

“The results of this preclinical study provide supportive evidence of the safety of Comera’s lead caffeine-based SQore excipient when administered as a subcutaneous (SQ) biologic drug product formulation with a monoclonal antibody (mAb).”

While the headline came out on the 13th, momentum has begun to flow this week. A more extensive study, SEQURUS-2, has already started to provide a “statistically robust evaluation” of caffeine on the PK of SQ-administered ipilimumab. Topline study results will be presented at the 14th Annual Bioprocessing Summit in mid-August. So the clock has begun ticking, and CMRA stock continues hitting new July highs.

Athersys, Inc. (NASDAQ: ATHX)

best penny stocks to buy biotech stocks Athersys ATHX stockchart

The exciting thing about penny stocks is that you can have one that slides for months, hits new 52-week lows, then seemingly out of nowhere, explodes. That is the case with Athersys in the stock market today. Shares of ATHX stock recently tested fresh lows on Tuesday but have bounced back nearly 100%.

[Read More] What to Know About Buying Penny Stocks on July 28th

What’s going on with Athersys? This week the company announced its next round of financial results. August 11th, after the close, is the time to mark down if ATHX stock is on your radar. The company is developing its MultiStem cell therapy product for neurological, inflammatory, immune, and cardiovascular indications. Several trials are currently ongoing evaluating its regenerative potential.

In the most recent Key Opinion Leader panel events, Athersys discussed its TREASURE study studying MultiStem for ischemic stroke. With the upcoming event in August, eyes could be on ATHX stock in hopes of new data or guidance on its pipeline.


best penny stocks to buy biotech stocks InflaRx IFRX stockchart

Is InflaRX on your penny stocks list today? If so, you probably saw headlines earlier in the week regarding an Emergency Use Authorization application announced for its vilobelimab. The company reported plans for the EUA application for using its candidate to treat critically ill COVID-19 patients. The move came after encouraging FDA interactions were held in a Type B meeting.

“Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients,” said Prof. Niels C. Riedemann, CEO and Founder of InflaRx in this week’s update.

Vilobelimab also received FDA Fast Track designation in treating ulcerative pyoderma gangrenosum. The skin disorder is being studied after the application of the drug candidate. With multiple use cases, new designations, and current studies in process and planned, there could be several things to follow with IFRX stock.

Revelation Biosciences Inc. (NASDAQ: REVB)

best penny stocks to buy biotech stocks Revelation Biosciences REVB stockchart

Shares of REVB stock popped late in the week this week, thanks to a turnaround in sentiment. Revelation specializes in immunologic-based therapies and recently announced a $5 million offering to push the ball down the field with the development of its REVTx-99b, REVTx-200, and REVTx-300 treatment platforms.

[Read More] Penny Stocks To Buy Now? 4 To Watch During July Fed Announcement

Since the offering is expected to close today, REVB stock is back in focus with new cash in hand. Its lead candidate, REVTx-99b, recently completed the dosing of its Phase 1b CLEAR clinical study. In a mid-June update, James Rolke, Chief Executive Officer of Revelation, explained, “We are excited to complete enrollment in this study and look forward to reporting the results in the third quarter of 2022.”

In true fashion, the company reported this data on July 22nd after the closing bell. The primary endpoint to evaluate the effects of REVTx-99b versus placebo on safety and tolerability was met. Now the plan is to assess the treatment candidate further.

Chimerix (NASDAQ: CMRX)

best penny stocks to buy biotech stocks Chimerix CMRX stockchart

Monkeypox stocks are still heating up the newsfeeds in the stock market today. Following earlier reports that the WHO declared the monkeypox spread a Global Health Emergency, this basket of biotech stocks has flourished in recent weeks. Led by the likes of Siga Technologies (NASDAQ: SIGA), plenty of cheaper stocks with a monkeypox treatment platform are gaining steam.

Emergent BioSolutions Inc. (NYSE: EBS), another monkeypox stock to watch, bought exclusive worldwide rights to Chimerix’s Tembexa. In a May update, Paul Williams, SVP government/MCM business at Emergent, said, “This transaction expands and further diversifies our medical countermeasures business with the addition of a small molecule therapeutic that aligns with the government’s smallpox preparedness strategy.”

With exposure to the latest monkeypox trend, CMRX is one of the penny stocks to watch. Keep in mind that since many of these companies are moving on speculation and broad headlines, sentiment and price movement, for that matter, can quickly change.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Spread & Containment

$265 Billion In Added Value To Evaporate From Germany Economy Amid Energy Crisis, Study Warns

$265 Billion In Added Value To Evaporate From Germany Economy Amid Energy Crisis, Study Warns

A new report published by the Employment Research…



$265 Billion In Added Value To Evaporate From Germany Economy Amid Energy Crisis, Study Warns

A new report published by the Employment Research (IAB) on Tuesday outlines how Germany's economy will lose a whopping 260 billion euros ($265 billion) in added value by the end of the decade due to high energy prices sparked by Russia's invasion of Ukraine which will have severe ramifications on the labor market, according to Reuters

IAB said Germany's price-adjusted GDP could be 1.7% lower in 2023, with approximately 240,000 job losses, adding labor market turmoil could last through 2026. It expects the labor market will begin rehealing by 2030 with 60,000 job additions.

The report pointed out the hospitality industry will be one of the biggest losers in the coming downturn that the coronavirus pandemic has already hit. Consumers who have seen their purchasing power collapse due to negative real wage growth as the highest inflation in decades runs rampant through the economy will reduce spending. 

IAB said energy-intensive industries, such as chemical and metal industries, will be significantly affected by soaring power prices. 

In one scenario, IAB said if energy prices, already up 160%, were to double again, Germany's economic output would crater by nearly 4% than it would have without energy supply disruptions from Russia. Under this assumption, 660,000 fewer people would be employed after three years and still 60,000 fewer in 2030. 

This week alone, German power prices hit record highs as a heat wave increased demand, putting pressure on energy supplies ahead of winter. 

Rising power costs are putting German households in economic misery as economic sentiment across the euro-area economy tumbled to a new record low. What happens in Germany tends to spread to the rest of the EU. 

There are concerns that a sharp weakening of growth in Germany could trigger stagflation as German inflation unexpectedly re-accelerated in July, with EU-Harmonized CPI rising 8.5% YoY. 

Germany is facing an unprecedented energy crisis as Russian natural gas cuts via the Nord Stream 1 pipeline will reverse the prosperity many have been accustomed to as the largest economy in Europe. 

"We are facing the biggest crisis the country has ever had. We have to be honest and say: First of all, we will lose the prosperity that we have had for years," Rainer Dulger, head of the Confederation of German Employers' Associations, warned last month. 

Besides Dulger, Economy Minister Robert Habeck warned of a "catastrophic winter" ahead over Russian NatGas cut fears.

Other officials and experts forecast bankruptcies, inflation, and energy rationing this winter that could unleash a tsunami of shockwaves across the German economy.  

Yasmin Fahimi, the head of the German Federation of Trade Unions, warned last month:

"Because of the NatGas bottlenecks, entire industries are in danger of permanently collapsing: aluminum, glass, the chemical industry." 

IAB's report appears to be on point as the German economy seems to be diving head first into an economic crisis. Much of this could've been prevented, but Europe and the US have been so adamant about slapping Russia with sanctions that have embarrassingly backfired. 

Tyler Durden Wed, 08/10/2022 - 04:15

Read More

Continue Reading


“Anything But A Cashless Society”: Physical Money Makes Comeback As UK Households Battle Inflation

"Anything But A Cashless Society": Physical Money Makes Comeback As UK Households Battle Inflation

The World Economic Forum (WEF) has been…



"Anything But A Cashless Society": Physical Money Makes Comeback As UK Households Battle Inflation

The World Economic Forum (WEF) has been pushing hard for a 'cashless society' in a post-pandemic world, though physical money has made a comeback in at least one European country as consumers increasingly use notes and coins to help them balance household budgets amid an inflationary storm

Britain's Post Office released a report Monday that revealed even though the recent accelerated use of cards and digital payments on smartphones, demand for cash surged this summer, according to The Guardian. It said branches handled £801mln in personal cash withdrawals in July, an increase of 8% over June. The yearly change on last month's figures was up 20% versus the July 2021 figure of £665mln.

Across the Post Office's 11,500 branches, £3.31bln in cash was deposited and withdrawn in July -- a record high for any month dating back over three centuries of operations. 

The report pointed out that increasing physical cash demand was primarily due to more people managing their budgets via notes and coins on a "day-by-day basis." It said some withdrawals were from vacationers needing cash for "staycations" in the UK. About 600,000 cash payouts totaling £90mln were from people who received power bill support from the government, the Post Office noted. 

Britain is "anything but a cashless society," according to the Post Office's banking director Martin Kearsley.

"We're seeing more and more people increasingly reliant on cash as the tried and tested way to manage a budget. Whether that's for a staycation in the UK or if it's to help prepare for financial pressures expected in the autumn, cash access in every community is critical," Kearsley said.

We noted in February 2021, UK's largest ATM network saw plummeting demand as consumers reduced cash usage. At the time, we asked this question: "How long will the desire for good old-fashioned bank notes last?

... and the answer is not long per the Post Office's new report as The Guardian explains: "inflation going up and many bills expected to rise further – has led a growing numbers of people to turn once again to cash to help them plan their spending." 

So much for WEF, central banks, and major corporations pushing for cashless societies worldwide, more importantly, trying to usher in a hyper-centralized CBDC dystopia. With physical cash back in style in the UK, the move towards a cashless society could be a much more challenging task for elites than previously thought. 

Tyler Durden Wed, 08/10/2022 - 02:45

Read More

Continue Reading


Something Just Doesn’t Add Up In Chinese Trade Data

Something Just Doesn’t Add Up In Chinese Trade Data

By Ye Xie, Bloomberg markets live commentator and reporter

An unusual discrepancy has…



Something Just Doesn’t Add Up In Chinese Trade Data

By Ye Xie, Bloomberg markets live commentator and reporter

An unusual discrepancy has showed up in two sets of trade data in China. Depending on which official sources you use, China’s trade surplus, could either be overstated or under-reported by a staggering $166 billion over the past year.

China watchers cannot fully explain the mystery. It’s as if Chinese residents bought a lot of stuff overseas, and instead of shipping the items home, they were kept abroad for some reason.  

China’s exports have been surprisingly resilient, despite a slowing global economy and Covid disruptions. On Monday, General Administration of Customs data showed China’s exports increased 18% in July from a year earlier. In contrast, imports grew only 2.3%, reflecting weak domestic demand.

The result is China’s trade surplus keeps swelling, which has underpinned the yuan by offsetting capital outflows. The surplus over the past year amounted to a record $864 billion, more than double the level at the end of 2019.

But when comparing the Customs data with that from the State Administration of Foreign Exchange (SAFE), a different picture emerges. The SAFE data shows the surplus is growing at a much slower pace -- about 20% less than the customs figure

The two data sets used to track each other closely. SAFE typically reports fewer imports, thus a higher surplus, because it excludes costs, insurance and freight from the value of goods imported, in line with the international standard practice, Adam Wolfe, an economist at Absolute Strategy Research, noted.

The other adjustments that SAFE does include:

  • It only records transactions that involve a change of ownership;
  • It adjusts for returned items;
  • It adds goods bought and resold abroad that don’t cross China’s border, but result in income for a Chinese entity -- a practice known  as “merchanting.”

The relationship between the two data sets has flipped since 2021, as SAFE reported higher imports, resulting in a smaller surplus than the Customs data.

It’s particularly odd because it happened at a time when shipping costs skyrocketed. When SAFE removes freight and insurance costs, it would have resulted in even lower, not higher, imports.

Taken at face value, the discrepancy suggests that somebody in China “bought” lots of goods from abroad, but they have never arrived in China. These transactions would be recorded by SAFE as imports, but not at the Customs office.

Craig Botham at Pantheon Macroeconomics, suspects that Covid-19 may be playing a role here. Foreign firms unable to manufacture in factories elsewhere during the pandemic might have transferred materials to China for assembly, a transaction excluded by SAFE.

Could Chinese buyers overstate their foreign purchases to SAFE, which regulates the capital account, so they can move money out of the country? The cross-border transactions show there was widespread overpaying for imports in 2014-2015, during a period of intense capital flight, but not at the moment, Wolfe pointed out.

Source: Absolute Strategy Research

The bottom line is that there aren’t many good explanations. As Alex Etra, a senior strategist at Exante Data, said, there’s “no smoking gun” to suggest something fishy is going on.

It’s another mysterious puzzle waiting to be solved.

Tyler Durden Tue, 08/09/2022 - 22:28

Read More

Continue Reading